Skip to main content
Equibles
ALUR logo

ALUR · Allurion Technologies, Inc. · Investor Relations

Track ALUR — free

Use ALUR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALUR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 -0.29 (-42.62%) At close · Mar 9
Rebalance outlook locked
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the amount and timing of such financings are uncertain, the Company has concluded that management’s plans do not alleviate substantial doubt about its ability to continue as a going concern for a reasonable period of time.”
View the 10-Q filed May 15, 2026
Market Cap
$2.01M
Shares
1.00M
Volume · Mar 9 392.2K Avg daily vol (3M) —

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-03-02 Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
2026-02-24 Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
2026-02-23 Allurion Receives U.S. FDA Approval
2026-02-03 Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
2026-01-12 Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
2025-11-25 Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
2025-11-20 New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
2025-11-18 Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
2025-11-12 Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-11 Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Past events

Date Event Type
2025-11-12 Allurion Third Quarter Earnings Call Earnings call
2025-08-13 Allurion Second Quarter Earnings Call Earnings call
2025-06-04 Jefferies Global Healthcare Conference Conference
2025-05-14 Allurion First Quarter Earnings Call Earnings call
2025-03-26 Allurion Fourth Quarter Earnings Call Earnings call
2025-03-03 TD Cowen's 45th Annual Health Care Conference Conference
2024-11-13 Allurion Third Quarter Earnings Call Earnings call
2024-08-13 Allurion Second Quarter Earnings Call Earnings call
2024-06-13 Sidoti Small Cap Virtual Conference Conference
2024-06-05 Jefferies Global Healthcare Conference Conference
2024-05-14 Allurion First Quarter Earnings Call Earnings call
2024-03-21 Allurion Fourth Quarter Earnings Call Earnings call
2024-03-13 34th Annual Oppenheimer Healthcare MedTech & Services Conference Conference
2024-03-05 Cowen’s 44th Annual Health Care Conference Conference
2023-11-13 Allurion Third Quarter Earnings Call Earnings call
2023-06-07 Jefferies Healthcare Conference Conference

Source: https://investors.allurion.com/secure.aspx?return=%2foverview%2fdefault.aspx

Key facts CIK 1964979 CUSIP 02008G300 Visit website Investor relations